The Safe Layer of Botulinum Neurotoxin Type A Injection in treating masseteric hypertrophy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029174

Enrollment

Unknown

Registered

2020-01-17

Start date

2020-01-13

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertrophy of masseter

Interventions

Two sides:Botulinum Neurotoxin Type A Injection: Left deep injection, right shallow injection versus right side deep injection, left side shallow injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. aged>18 years; 2. benign masseteric hypertrophy.

Exclusion criteria

Exclusion criteria: Diseases of the blood system, nervous system, immune system, coagulopathy; history of mental illness; pregnant and lactating women; communication difficulties; poor coordination and contraindications to corresponding surgery.

Design outcomes

Primary

Measure	Time frame
masseteric thickness;	—

Countries

China

Contacts

Public ContactNanze Yu

Division of Plastic and Reconstructive Surgery Peking Union Medical College Hospital

yunanze@163.com+86 15910522916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026